**Publication Instructions:**

**BMT CTN Protocol 1506**
**- Primary and Ancillary Studies –**

---

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 1506.

**Acknowledgment Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

"Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Astellas Pharma Global Development, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties."

**The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:**
The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

**Review Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

**BMT CTN**: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

**Astellas ("Contributor") Requirements:**

Manuscript Review Period. Not less than 30 days prior to the earlier of Publication or submission for Publication of any Manuscript, NMDP or the other members of BMT CTN DCC shall, or shall cause the Principal Investigator to, provide Contributor with a copy of the Manuscript. If the Manuscript is an abstract, presentation, or poster, Contributor shall use reasonable efforts to complete its review as promptly as possible. NMDP or the other members of BMT CTN DCC, as applicable, shall consider in good faith any comments submitted by Contributor regarding the content thereof, and shall delete any Contributor Confidential Information and any Study Deliverables Confidential Information. In addition, at Contributor's request, NMDP or the other members of BMT CTN DCC, as applicable, shall delay (and shall cause the Principal Investigator to delay) Publication or submission for Publication of the Manuscript, as the case may be, for an additional 45 days to allow patent applications to be filed, to the extent Contributor is allowed to seek patent protection pursuant to Section **Error! Reference source not found.**, on one or more Inventions not previously Published that are disclosed in the Manuscript. Notwithstanding the foregoing, NMDP, BMT CTN DCC or

Participating Sites may Publish, at their own discretion, any Study Deliverables Confidential Information at any time after 36 months from the date of primary database lock, including without limitation, the de-identified individual patient supporting data used to generate the analyses in such Publication in a public database as required by NIH policies, regulations and applicable laws.

**For correlative studies utilizing biospecimens obtained from the NHLBI Biologic Specimen Repository (operated by the NMDP) and/or clinical data obtained from the NHLBI Data Repository Information Coordinating Center, include the following as applicable**:

If the Research Plan involves collaboration with Study Investigators, acknowledge the source of the data by including language similar to the following either in the acknowledgement or in the text of the manuscript:

*"This manuscript was prepared using BMT CTN 1506 Research Materials obtained from the NHLBI."*

If the Research Plan does not involve collaboration with Study investigators, or if the Study has ended, use the following language:

*"This manuscript was prepared using BMT CTN 1506 Research Materials obtained from the NHLBI Biologic Specimen Repository (Operated by the NMDP) and NHLBI Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BMT CTN 1506 or the NHLBI."*

Manuscripts and abstracts resulting from the Research Plan should not use the name of the Study in the title of the manuscript/abstract unless the title clearly denotes the source of the Research Materials as being from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.

**Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.**